MiniMed Group, Inc. (MMED)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XFRA 
MiniMed: Next-Generation Diabetes Platform Supports A Buy Rating
MiniMed Group, a Medtronic spin-off, is rated a buy with an FY 2027 price target of $19, implying 15% upside. MMED's double-digit revenue growth is driven by strong international adoption, expanding CGM attach rates, and timely product launches ahead of schedule. Despite gross margin compression and widened net losses in FY 2026, robust liquidity from IPO proceeds supports ongoing product rollouts and operational improvements.
MiniMed Group Q4 Earnings Call Highlights
MiniMed Group NASDAQ: MMED reported record fiscal 2026 revenue and outlined a slate of product launches it said will support faster growth in fiscal 2027, as management held the company's first earnings call as a standalone public company following its March IPO.
MMED's Latest Study Supports the Strength of 780G SmartGuard Algorithm
MiniMed study results show MiniMed 780G delivering consistent glycemic outcomes across sensors, reinforcing SmartGuard's strength.
MiniMed initiated with ‘Buy' rating by Bank of America on pipeline-driven growth outlook
MiniMed Group (NASDAQ:MMED) has been initiated with a ‘Buy' rating by Bank of America, reflecting the view that the company is approaching a key inflection point following its recent separation from Medtronic. The analysts gave the company, which specializes in developing and manufacturing technology for diabetes management, a $27 price target, implying upside from current levels of about $14.
